SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-240257"
 

Sökning: id:"swepub:oai:DiVA.org:uu-240257" > Tumour volume reduc...

  • Dantonello, Tobias MPaediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germany (författare)

Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • 2014-09-27
  • Wiley,2015
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-240257
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-240257URI
  • https://doi.org/10.1002/pbc.25207DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BACKGROUND: Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes.PROCEDURE: Patients with IRSG-III RME <21 years and non-response (NR, <33% volume reduction) in five consecutive CWS-trials were analysed and compared with partial responders (PAR, ≥33% reduction). The NR was reviewed and sub-classified as Objective Response (OR, <0%-33% reduction) or Stable/Progressive Disease (SPD).RESULTS: Fifty-nine of 529 patients had NR (n = 34 OR, n = 25 SPD). Primary risk-factors including age, tumour size, and TN-classification did not differ between NR and PAR groups but NR had more patients with unfavourable sites comparatively (P = 0.04). There were no differences in primary risk-factors between OR and SPD. Significant factors associated with poor outcome in multivariate analysis were NR, TN-classification, age >10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n = 20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P < 0.001).CONCLUSION: Response to induction chemotherapy appears to be an important surrogate marker of poor outcome in patients with SPD largely due to ineffective local control.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Stark, MonikaPaediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germany (författare)
  • Timmermann, Beate (författare)
  • Fuchs, Jörg (författare)
  • Selle, Barbara (författare)
  • Linderkamp, Christin (författare)
  • Handgretinger, Rupert (författare)
  • Hagen, Rudolf (författare)
  • Feuchtgruber, Simone (författare)
  • Kube, Stefanie (författare)
  • Kosztyla, Daniel (författare)
  • Kazanowska, Bernarda (författare)
  • Ladenstein, Ruth (författare)
  • Niggli, Felix (författare)
  • Ljungman, Gustaf,1958-Uppsala universitet,Pediatrik,Barnonkologisk forskning/Ljungman(Swepub:uu)gustaflm (författare)
  • Bielack, Stefan S (författare)
  • Klingebiel, Thomas (författare)
  • Koscielniak, EwaPaediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, Germany (författare)
  • Paediatrics 5 (oncology, hematology, immunology), Olgahospital Klinikum Stuttgart, GermanyPediatrik (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Pediatric Blood & Cancer: Wiley62:1, s. 16-231545-50091545-5017

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy